Drug Search Results
More Filters [+]

4P-004

Alternative Names: 4P-004, 4P004
Latest Update: 2024-06-10
Latest Update Note: News Article

Product Description

4P004 is a GLP-1 analog, a potential first-in-class disease modifier drug for osteoarthritis (DMOAD), showing anti-inflammatory, anti-catabolic and anabolic properties. (Sourced from: https://4p-pharma.com/#pipeline)

Mechanisms of Action: GLP-1 Analogue

Novel Mechanism: Yes

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: 4Moving Biotech
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for 4P-004

Countries in Clinic: Belgium

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Osteoarthritis, Knee

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

LASARE

P1

Completed

Osteoarthritis, Knee

2023-10-31

Recent News Events